Immunotherapeutic interleukin-6 or interleukin-6 receptor blockade in cancer: Challenges and opportunities

Current Medicinal Chemistry

Volumn 25, Issue 36, 2018, Pages 4785-4806

  Kampan, Nirmala Chandralega ^a,b,c   Xiang, Sue D ^a,e   McNally, Orla M ^b   Stephens, Andrew N ^a,d,e   Quinn, Michael A ^b   Plebanski, Magdalena ^a  

^a MONASH UNIVERSITY   (Australia)

^b ROYAL WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^d HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e EPWORTH HEALTHCARE   (Australia)

Author keywords

Cancer; IL 6; IL 6 receptor; Immunotherapy; JAK STAT signalling pathway; Monoclonal antibodies; Pro inflammatory cytokine; STAT 3

Indexed keywords

20,21 EPOXY RESIBUFOGENIN 3 ACETATE; ANTINEOPLASTIC MONOCLONAL ANTIBODY; AZINTREL; BE 8; CLAZAKIZUMAB; CYTOKINE RECEPTOR ANTAGONIST; ELSILIMOMAB; GLYCOPROTEIN GP 130; GLYCOPROTEIN GP 130 FC; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; INTERLEUKIN 6; INTERLEUKIN 6 ANTAGONIST; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ANTAGONIST; INTERLEUKIN 6 RECEPTOR SUPERANTAGONIST 7; SANT 7; SARILUMAB; SILTUXIMAB; TOCILIZUMAB; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; DRUG TARGETING; HUMAN; IMMUNE RELATED RESPONSE CRITERIA; INFLAMMATION; MALIGNANT NEOPLASM; MOUTH SQUAMOUS CELL CARCINOMA; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; PROSTATE CANCER; PROTEIN FUNCTION; RENAL CELL CARCINOMA; REVIEW; SIGNAL TRANSDUCTION; SOLID MALIGNANT NEOPLASM; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECT; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM;

ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOTHERAPY; INFLAMMATION; INTERLEUKIN-6; NEOPLASMS; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 85058896721     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867324666170712160621     Document Type: Review

References (161)

1. Balkwill, F.; Mantovani, A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357(9255), 539-545.
2. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell, 2011, 144(5), 646-674.
3. Sato, E.; Olson, S.H.; Ahn, J.; Bundy, B.; Nishikawa, H.; Qian, F.; Jungbluth, A.A.; Frosina, D.; Gnjatic, S.; Am-brosone, C.; Kepner, J.; Odunsi, T.; Ritter, G.; Lele, S.; Chen, Y.T.; Ohtani, H.; Old, L.J.; Odunsi, K. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA, 2005, 102(51), 18538-18543.
4. Aggarwal, B.B.; Vijayalekshmi, R.V.; Sung, B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin. Cancer Res., 2009, 15(2), 425-430.
5. Ekbom, A.; Helmick, C.; Zack, M.; Adami, H.O. Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet, 1990, 336(8711), 357-359.
6. Choi, P.M.; Zelig, M.P. Similarity of colorectal cancer in Crohn’s disease and ulcerative colitis: Implications for carcinogenesis and prevention. Gut, 1994, 35(7), 950-954.
7. Klampfer, L. Cytokines, inflammation and colon cancer. Curr. Cancer Drug Targets, 2011, 11(4), 451-464.
8. Nash, M.A.; Ferrandina, G.; Gordinier, M.; Loercher, A.; Freedman, R.S. The role of cytokines in both the normal and malignant ovary. Endocr. Relat. Cancer, 1999, 6(1), 93-107.
9. Macciò, A.; Madeddu, C. Inflammation and ovarian cancer. Cytokine, 2012, 58(2), 133-147.
10. Fleming, J.S.; Beaugié, C.R.; Haviv, I.; Chenevix-Trench, G.; Tan, O.L. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol. Cell. Endocrinol., 2006, 247(1-2), 4-21.
11. Clendenen, T.V.; Lundin, E.; Zeleniuch-Jacquotte, A.; Koenig, K.L.; Berrino, F.; Lukanova, A.; Lokshin, A.E.; Idahl, A.; Ohlson, N.; Hallmans, G.; Krogh, V.; Sieri, S.; Muti, P.; Marrangoni, A.; Nolen, B.M.; Liu, M.; Shore, R.E.; Arslan, A.A. Circulating inflammation markers and risk of epithelial ovarian cancer. Cancer Epidemiol. Biomarkers Prev., 2011, 20(5), 799-810.
12. Zamarron, B.F.; Chen, W. Dual roles of immune cells and their factors in cancer development and progression. Int. J. Biol. Sci., 2011, 7(5), 651-658.
13. Raman, D.; Baugher, P.J.; Thu, Y.M.; Richmond, A. Role of chemokines in tumor growth. Cancer Lett., 2007, 256(2), 137-165.
14. Germano, G.; Allavena, P.; Mantovani, A. Cytokines as a key component of cancer-related inflammation. Cytokine, 2008, 43(3), 374-379.
15. Lin, M-T.; Juan, C-Y.; Chang, K-J.; Chen, W-J.; Kuo, M-L. IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1. Carcinogenesis, 2001, 22(12), 1947-1953.
16. Yeoh, G.C.; Ernst, M.; Rose-John, S.; Akhurst, B.; Payne, C.; Long, S.; Alexander, W.; Croker, B.; Grail, D.; Mat-Mat- thews, V.B. Opposing roles of gp130-mediated STAT-3 and ERK-1/ 2 signaling in liver progenitor cell migration and proliferation. Hepatology, 2007, 45(2), 486-494. thews,
17. Martignoni, M.E.; Kunze, P.; Hildebrandt, W.; Künzli, B.; Berberat, P.; Giese, T.; Klöters, O.; Hammer, J.; Büchler, M.W.; Giese, N.A.; Friess, H. Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin. Cancer Res., 2005, 11(16), 5802-5808.
18. Bollrath, J.; Phesse, T.J.; von Burstin, V.A.; Putoczki, T.; Bennecke, M.; Bateman, T.; Nebelsiek, T.; Lundgren-May, T.; Canli, O.; Schwitalla, S.; Matthews, V.; Schmid, R.M.; Kirchner, T.; Arkan, M.C.; Ernst, M.; Greten, F.R. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell, 2009, 15(2), 91-102.
19. Wei, L-H.; Kuo, M-L.; Chen, C-A.; Chou, C-H.; Lai, K-B.; Lee, C-N.; Hsieh, C-Y. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene, 2003, 22(10), 1517-1527.
20. Ibrahim, S.A.; El-Ghonaimy, E.A.; Hassan, H.; Mahana, N.; Mahmoud, M.A.; El-Mamlouk, T.; El-Shinawi, M.; Mohamed, M.M. Hormonal-receptor positive breast cancer: IL-6 augments invasion and lymph node metastasis via stimulating cathepsin B expression. J. Adv. Res., 2016, 7(5), 661-670.
21. Zou, M.; Zhang, X.; Xu, C. IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3′-diindolylmethane in ovarian cancer cells. Cell Oncol. (Dordr.), 2016, 39(1), 47-57.
22. Kawano, M.; Hirano, T.; Matsuda, T.; Taga, T.; Horii, Y.; Iwato, K.; Asaoku, H.; Tang, B.; Tanabe, O.; Tanaka, H. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature, 1988, 332(6159), 83-85.
23. Akira, S.; Taga, T.; Kishimoto, T. Interleukin-6 in biology and medicine. Adv. Immunol., 1993, 54, 1-78.
24. Kishimoto, T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res. Ther., 2006, 8(2), S2.
25. Lotz, M.; Jirik, F.; Kabouridis, P.; Tsoukas, C.; Hirano, T.; Kishimoto, T.; Carson, D.A. B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J. Exp. Med., 1988, 167(3), 1253-1258.
26. Heinrich, P.C.; Behrmann, I.; Haan, S.; Hermanns, H.M.; Müller-Newen, G.; Schaper, F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J., 2003, 374(Pt 1), 1-20.
27. Scheller, J.; Rose-John, S. Interleukin-6 and its receptor: From bench to bedside. Med. Microbiol. Immunol. (Berl.), 2006, 195(4), 173-183.
28. Wolvekamp, M.C.; Marquet, R.L. Interleukin-6: historical background, genetics and biological significance. Immunol. Lett., 1990, 24(1), 1-9.
29. Heinrich, P.C.; Castell, J.V.; Andus, T. Interleukin-6 and the acute phase response. Biochem. J., 1990, 265(3), 621-636.
30. Jones, S.A.; Horiuchi, S.; Topley, N.; Yamamoto, N.; Fuller, G.M. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J., 2001, 15(1), 43-58.
31. Hibi, M.; Murakami, M.; Saito, M.; Hirano, T.; Taga, T.; Kishimoto, T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell, 1990, 63(6), 1149-1157.
32. Yoshizaki, K. Nishimoto, N.; Mihara, M.; Kishimoto, T. Springer seminars in immunopathology; Springer, 1998, Vol. 20, pp. 247-259.
33. Romano, M.; Sironi, M.; Toniatti, C.; Polentarutti, N.; Fruscella, P.; Ghezzi, P.; Faggioni, R.; Luini, W.; van Hins-bergh, V.; Sozzani, S.; Bussolino, F.; Poli, V.; Ciliberto, G.; Mantovani, A. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity, 1997, 6(3), 315-325.
34. Hurst, S.M.; Wilkinson, T.S.; McLoughlin, R.M.; Jones, S.; Horiuchi, S.; Yamamoto, N.; Rose-John, S.; Fuller, G.M.; Topley, N.; Jones, S.A. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity, 2001, 14(6), 705-714.
35. Kudo, O.; Sabokbar, A.; Pocock, A.; Itonaga, I.; Fujikawa, Y.; Athanasou, N.A. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone, 2003, 32(1), 1-7.
36. Legendre, F.; Dudhia, J.; Pujol, J-P.; Bogdanowicz, P. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of type II col-lagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression. J. Biol. Chem., 2003, 278(5), 2903-2912.
37. Giraudo, E.; Arese, M.; Toniatti, C.; Strasly, M.; Primo, L.; Mantovani, A.; Ciliberto, G.; Bussolini, F. IL-6 is an in vitro and in vivo autocrine growth factor for middle T anti-gen-transformed endothelial cells. J. Immunol., 1996, 157(6), 2618-2623.
38. Barton, B.E. IL-6: Insights into novel biological activities. Clin. Immunol. Immunopathol., 1997, 85(1), 16-20.
39. Boccadoro, M.; Gavarotti, P.; Ciaiolo, C.; Golzio, F.; Omedè, P.; Redoglia, V.; Pileri, A. Cytokinetic studies in human myeloma. Basic Appl. Histochem., 1986, 30(2), 233-237.
40. van Dam, M.; Müllberg, J.; Schooltink, H.; Stoyan, T.; Brakenhoff, J.P.; Graeve, L.; Heinrich, P.C.; Rose-John, S. Structure-function analysis of interleukin-6 utilizing hu-man/murine chimeric molecules. Involvement of two separate domains in receptor binding. J. Biol. Chem., 1993, 268(20), 15285-15290.
41. Horiuchi, S.; Koyanagi, Y.; Zhou, Y.; Miyamoto, H.; Tanaka, Y.; Waki, M.; Matsumoto, A.; Yamamoto, M.; Yamamoto, N. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur. J. Immunol., 1994, 24(8), 1945-1948.
42. Culig, Z. Cytokine disbalance in common human cancers. Biochim. Biophys. Acta, 2011, 1813(2), 308-314.
43. Chalaris, A.; Garbers, C.; Rabe, B.; Rose-John, S.; Scheller, J. The soluble interleukin 6 receptor: Generation and role in inflammation and cancer. Eur. J. Cell Biol., 2011, 90(6-7), 484-494.
44. Ward, L.D.; Howlett, G.J.; Discolo, G.; Yasukawa, K.; Hammacher, A.; Moritz, R.L.; Simpson, R.J. High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. J. Biol. Chem., 1994, 269(37), 23286-23289.
45. Rawlings, J.S.; Rosler, K.M.; Harrison, D.A. The JAK/STAT signaling pathway. J. Cell Sci., 2004, 117(Pt 8), 1281-1283.
46. Krebs, D.L.; Hilton, D.J. SOCS: Physiological suppressors of cytokine signaling. J. Cell Sci., 2000, 113(Pt 16), 2813-2819.
47. Krebs, D.L.; Hilton, D.J. SOCS proteins: Negative regulators of cytokine signaling. Stem Cells, 2001, 19(5), 378-387.
48. Chung, C.D.; Liao, J.; Liu, B.; Rao, X.; Jay, P.; Berta, P.; Shuai, K. Specific inhibition of Stat3 signal transduction by PIAS3. Science, 1997, 278(5344), 1803-1805.
49. Steelman, L.S.; Pohnert, S.C.; Shelton, J.G.; Franklin, R.A.; Bertrand, F.E.; McCubrey, J.A. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia, 2004, 18(2), 189-218.
50. Yang, L.; Wang, L.; Lin, H-K.; Kan, P-Y.; Xie, S.; Tsai, M-Y.; Wang, P-H.; Chen, Y-T.; Chang, C. Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem. Biophys. Res. Commun., 2003, 305(3), 462-469.
51. Pollard, J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer, 2004, 4(1), 71-78.
52. Kamimura, D. Ishihara, K. Hirano Reviews of physiology, biochemistry and pharmacology; Springer, 2003, pp. 1-38.
53. Heinrich, P.C.; Behrmann, I.; Müller-Newen, G.; Schaper, F.; Graeve, L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J., 1998, 334(Pt 2), 297-314.
54. DeNardo, D.G.; Andreu, P.; Coussens, L.M. Interactions between lymphocytes and myeloid cells regulate pro-versus anti-tumor immunity. Cancer Metastasis Rev., 2010, 29(2), 309-316.
55. Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, inflammation, and cancer. Cell, 2010, 140(6), 883-899.
56. Karnoub, A.E.; Weinberg, R.A. Chemokine networks and breast cancer metastasis. Breast Dis., 2006-2007, 26(1), 75-85.
57. Qian, B-Z.; Pollard, J.W. Macrophage diversity enhances tumor progression and metastasis. Cell, 2010, 141(1), 39-51.
58. Naugler, W.E.; Karin, M. The wolf in sheep’s clothing: The role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med., 2008, 14(3), 109-119.
59. Santer, F.R.; Malinowska, K.; Culig, Z.; Cavarretta, I.T. Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr. Relat. Cancer, 2010, 17(1), 241-253.
60. Suchi, K.; Fujiwara, H.; Okamura, S.; Okamura, H.; Ume-hara, S.; Todo, M.; Furutani, A.; Yoneda, M.; Shiozaki, A.; Kubota, T.; Ichikawa, D.; Okamoto, K.; Otsuji, E. Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells. Anticancer Res., 2011, 31(1), 67-75.
61. Patchen, M.L.; MacVittie, T.J.; Williams, J.L.; Schwartz, G.N.; Souza, L.M. Administration of interleukin-6 stimulates multilineage hematopoiesis and accelerates recovery from radiation-induced hematopoietic depression. Blood, 1991, 77(3), 472-480.
62. Kim, S.Y.; Kang, J.W.; Song, X.; Kim, B.K.; Yoo, Y.D.; Kwon, Y.T.; Lee, Y.J. Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell. Signal., 2013, 25(4), 961-969.
63. Gabrilovich, D.I.; Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol., 2009, 9(3), 162-174.
64. Peranzoni, E.; Zilio, S.; Marigo, I.; Dolcetti, L.; Zanovello, P.; Mandruzzato, S.; Bronte, V. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol., 2010, 22(2), 238-244.
65. Ando, M.; Uehara, I.; Kogure, K.; Asano, Y.; Nakajima, W.; Abe, Y.; Kawauchi, K.; Tanaka, N. Interleukin 6 enhances glycolysis through expression of the glycolytic enzymes hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3. J. Nippon Med. Sch., 2010, 77(2), 97-105.
66. Hashizume, M.; Yoshida, H.; Koike, N.; Suzuki, M.; Mihara, M. Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor. Ann. Rheum. Dis., 2010, 69(4), 741-746.
67. Barton, B.E. IL-6-like cytokines and cancer cachexia: Consequences of chronic inflammation. Immunol. Res., 2001, 23(1), 41-58.
68. Fearon, K.; Strasser, F.; Anker, S.D.; Bosaeus, I.; Bruera, E.; Fainsinger, R.L.; Jatoi, A.; Loprinzi, C.; MacDonald, N.; Mantovani, G.; Davis, M.; Muscaritoli, M.; Ottery, F.; Radbruch, L.; Ravasco, P.; Walsh, D.; Wilcock, A.; Kaasa, S.; Baracos, V.E. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol., 2011, 12(5), 489-495.
69. Yao, X.; Huang, J.; Zhong, H.; Shen, N.; Faggioni, R.; Fung, M.; Yao, Y. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol. Ther., 2014, 141(2), 125-139.
70. Bellone, G.; Smirne, C.; Mauri, F.A.; Tonel, E.; Carbone, A.; Buffolino, A.; Dughera, L.; Robecchi, A.; Pirisi, M.; Emanuelli, G. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: Implications for survival. Cancer Immunol. Immunother., 2006, 55(6), 684-698.
71. Cardillo, M.R.; Ippoliti, F. Interleukin-6, interleukin-10 and heat shock protein-90 expression in renal epithelial neopla-sias and surrounding normal-appearing renal parenchyma. Int. J. Immunopathol. Pharmacol., 2007, 20(1), 37-46.
72. Nishimoto, N.; Sasai, M.; Shima, Y.; Nakagawa, M.; Matsumoto, T.; Shirai, T.; Kishimoto, T.; Yoshizaki, K. Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood, 2000, 95(1), 56-61.
73. Lauta, V.M. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer, 2003, 97(10), 2440-2452.
74. Ravishankaran, P.; Karunanithi, R. Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J. Surg. Oncol., 2011, 9(1), 18.
75. Yoshida, N.; Ikemoto, S.; Narita, K.; Sugimura, K.; Wada, S.; Yasumoto, R.; Kishimoto, T.; Nakatani, T. Interleukin-6, tumour necrosis factor α and interleukin-1β in patients with renal cell carcinoma. Br. J. Cancer, 2002, 86(9), 1396-1400.
76. Chung, Y.C.; Chang, Y.F. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J. Surg. Oncol., 2003, 83(4), 222-226.
77. Miki, C.; Konishi, N.; Ojima, E.; Hatada, T.; Inoue, Y.; Kusunoki, M. C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma. Dig. Dis. Sci., 2004, 49(6), 970-976.
78. Bataille, R.; Jourdan, M.; Zhang, X-G.; Klein, B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J. Clin. Invest., 1989, 84(6), 2008-2011.
79. Lu, Z.Y.; Brailly, H.; Wijdenes, J.; Bataille, R.; Rossi, J.F.; Klein, B. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood, 1995, 86(8), 3123-3131.
80. Klein, B.; Wijdenes, J.; Zhang, X-G.; Jourdan, M.; Boiron, J-M.; Brochier, J.; Liautard, J.; Merlin, M.; Clement, C.; Morel-Fournier, B. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood, 1991, 78(5), 1198-1204.
81. Emilie, D.; Wijdenes, J.; Gisselbrecht, C.; Jarrousse, B.; Billaud, E.; Blay, J-Y.; Gabarre, J.; Gaillard, J-P.; Brochier, J.; Raphael, M. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunode-ficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. Blood, 1994, 84(8), 2472-2479.
82. Blay, J-Y.; Rossi, J.F.; Wijdenes, J.; Menetrier-Caux, C.; Schemann, S.; Négrier, S.; Philip, T.; Favrot, M. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int. J. Cancer, 1997, 72(3), 424-430.
83. Moreau, P.; Harousseau, J.L.; Wijdenes, J.; Morineau, N.; Milpied, N.; Bataille, R. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br. J. Haematol., 2000, 109(3), 661-664.
84. Ataie-Kachoie, P.; Pourgholami, M.H.; Morris, D.L. Inhibition of the IL-6 signaling pathway: A strategy to combat chronic inflammatory diseases and cancer. Cytokine Growth Factor Rev., 2013, 24(2), 163-173.
85. Puchalski, T.; Prabhakar, U.; Jiao, Q.; Berns, B.; Davis, H.M. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (sil-tuximab) in patients with metastatic renal cell carcinoma. Clin. Cancer Res., 2010, 16(5), 1652-1661.
86. Davis, C.C.; Shah, K.S.; Lechowicz, M.J. Clinical development of siltuximab. Curr. Oncol. Rep., 2015, 17(7), 29.
87. Slyvant (Siltuximab) A clear path forward. Available from: https://www.sylvant.com/shared/product/sylvant/sylvant-dosing-and-administration-guide.pdf
88. Guo, Y.; Xu, F.; Lu, T.; Duan, Z.; Zhang, Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat. Rev., 2012, 38(7), 904-910.
89. Herrada, J.; Cabanillas, F.; Rice, L.; Manning, J.; Pugh, W. The clinical behavior of localized and multicentric Castleman disease. Ann. Intern. Med., 1998, 128(8), 657-662.
90. Bowne, W.B.; Lewis, J.J.; Filippa, D.A.; Niesvizky, R.; Brooks, A.D.; Burt, M.E.; Brennan, M.F. The management of unicentric and multicentric Castleman’s disease: A report of 16 cases and a review of the literature. Cancer, 1999, 85(3), 706-717.
91. Nishimoto, N.; Kanakura, Y.; Aozasa, K.; Johkoh, T.; Nakamura, M.; Nakano, S.; Nakano, N.; Ikeda, Y.; Sasaki, T.; Nishioka, K.; Hara, M.; Taguchi, H.; Kimura, Y.; Kato, Y.; Asaoku, H.; Kumagai, S.; Kodama, F.; Nakahara, H.; Hagi-hara, K.; Yoshizaki, K.; Kishimoto, T. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood, 2005, 106(8), 2627-2632.
92. van Rhee, F.; Stone, K.; Szmania, S.; Barlogie, B.; Singh, Z. Castleman disease in the 21st century: An update on diagnosis, assessment, and therapy. Clin. Adv. Hematol. Oncol., 2010, 8(7), 486-498.
93. van Rhee, F.; Rothman, M.; Ho, K.F.; Fleming, S.; Wong, R.S.; Fosså, A.; Dispenzieri, A.; Cavet, J.; Munshi, N.; Vermeulen, J.; Casper, C. Patient-reported outcomes for multicentric Castleman’s disease in a randomized, placebo-controlled study of siltuximab. Patient, 2015, 8(2), 207-216.
94. Klein, B.; Bataille, R. Cytokine network in human multiple myeloma. Hematol. Oncol. Clin. North Am., 1992, 6(2), 273-284.
95. Gaillard, J.P.; Bataille, R.; Brailly, H.; Zuber, C.; Yasukawa, K.; Attal, M.; Maruo, N.; Taga, T.; Kishimoto, T.; Klein, B. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur. J. Immunol., 1993, 23(4), 820-824.
96. Hunsucker, S.A.; Magarotto, V.; Kuhn, D.J.; Kornblau, S.M.; Wang, M.; Weber, D.M.; Thomas, S.K.; Shah, J.J.; Voorhees, P.M.; Xie, H.; Cornfeld, M.; Nemeth, J.A.; Orlowski, R.Z. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br. J. Haematol., 2011, 152(5), 579-592.
97. Kurzrock, R.; Voorhees, P.M.; Casper, C.; Furman, R.R.; Fayad, L.; Lonial, S.; Borghaei, H.; Jagannath, S.; Sokol, L.; Usmani, S.Z.; van de Velde, H.; Qin, X.; Puchalski, T.A.; Hall, B.; Reddy, M.; Qi, M.; van Rhee, F. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin. Cancer Res., 2013, 19(13), 3659-3670.
98. Suzuki, K.; Ogura, M.; Abe, Y.; Suzuki, T.; Tobinai, K.; Ando, K.; Taniwaki, M.; Maruyama, D.; Kojima, M.; Ku-roda, J.; Achira, M.; Iizuka, K. Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in re-lapsed/refractory multiple myeloma. Int. J. Hematol., 2015, 101(3), 286-294.
99. van Zaanen, H.C.; Koopmans, R.P.; Aarden, L.A.; Rensink, H.J.; Stouthard, J.M.; Warnaar, S.O.; Lokhorst, H.M.; van Oers, M.H. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J. Clin. Invest., 1996, 98(6), 1441-1448.
100. Voorhees, P.M.; Manges, R.F.; Sonneveld, P.; Jagannath, S.; Somlo, G.; Krishnan, A.; Lentzsch, S.; Frank, R.C.; Zweegman, S.; Wijermans, P.W.; Orlowski, R.Z.; Kranen-burg, B.; Hall, B.; Casneuf, T.; Qin, X.; van de Velde, H.; Xie, H.; Thomas, S.K. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br. J. Haematol., 2013, 161(3), 357-366.
101. San-Miguel, J.; Bladé, J.; Shpilberg, O.; Grosicki, S.; Maloisel, F.; Min, C.K.; Polo Zarzuela, M.; Robak, T.; Prasad, S.V.; Tee Goh, Y.; Laubach, J.; Spencer, A.; Mateos, M.V.; Palumbo, A.; Puchalski, T.; Reddy, M.; Uh-lar, C.; Qin, X.; van de Velde, H.; Xie, H.; Orlowski, R.Z. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood, 2014, 123(26), 4136-4142.
102. Orlowski, R.Z.; Gercheva, L.; Williams, C.; Sutherland, H.; Robak, T.; Masszi, T.; Goranova-Marinova, V.; Dimopou-los, M.A.; Cavenagh, J.D.; Špička, I.; Maiolino, A.; Suvo-rov, A.; Bladé, J.; Samoylova, O.; Puchalski, T.A.; Reddy, M.; Bandekar, R.; van de Velde, H.; Xie, H.; Rossi, J.F. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am. J. Hematol., 2015, 90(1), 42-49.
103. Angevin, E.; Tabernero, J.; Elez, E.; Cohen, S.J.; Bahleda, R.; van Laethem, J.L.; Ottensmeier, C.; Lopez-Martin, J.A.; Clive, S.; Joly, F.; Ray-Coquard, I.; Dirix, L.; Machiels, J.P.; Steven, N.; Reddy, M.; Hall, B.; Puchalski, T.A.; Bandekar, R.; van de Velde, H.; Tromp, B.; Vermeulen, J.; Kurzrock, R. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumours. Clin. Cancer Res., 2014, 20(8), 2192-2204.
104. Nakashima, J.; Tachibana, M.; Horiguchi, Y.; Oya, M.; Ohi-gashi, T.; Asakura, H.; Murai, M. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin. Cancer Res., 2000, 6(7), 2702-2706.
105. George, D.J.; Halabi, S.; Shepard, T.F.; Sanford, B.; Vogelzang, N.J.; Small, E.J.; Kantoff, P.W. The prognostic significance of plasma interleukin-6 levels in patients with me-me- tastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin. Cancer Res., 2005, 11(5), 1815-1820. tastatic
106. Michalaki, V.; Syrigos, K.; Charles, P.; Waxman, J. Serum levels of IL-6 and TNF-alpha correlate with clinicopa-thological features and patient survival in patients with prostate cancer. Br. J. Cancer, 2004, 90(12), 2312-2316.
107. Karkera, J.; Steiner, H.; Li, W.; Skradski, V.; Moser, P.L.; Riethdorf, S.; Reddy, M.; Puchalski, T.; Safer, K.; Prabhakar, U.; Pantel, K.; Qi, M.; Culig, Z. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate, 2011, 71(13), 1455-1465.
108. Fizazi, K.; De Bono, J.S.; Flechon, A.; Heidenreich, A.; Voog, E.; Davis, N.B.; Qi, M.; Bandekar, R.; Vermeulen, J.T.; Cornfeld, M.; Hudes, G.R. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur. J. Cancer, 2012, 48(1), 85-93.
109. Dorff, T.B.; Goldman, B.; Pinski, J.K.; Mack, P.C.; Lara, P.N., Jr; Van Veldhuizen, P.J., Jr; Quinn, D.I.; Vogelzang, N.J.; Thompson, I.M., Jr; Hussain, M.H. Clinical and correlative results of SWOG S0354: A phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin. Cancer Res., 2010, 16(11), 3028-3034.
110. Hudes, G.; Tagawa, S.T.; Whang, Y.E.; Qi, M.; Qin, X.; Puchalski, T.A.; Reddy, M.; Cornfeld, M.; Eisenberger, M. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Invest. New Drugs, 2013, 31(3), 669-676.
111. Dobrzycka, B.; Mackowiak-Matejczyk, B.; Terlikowska, K.M.; Kulesza-Bronczyk, B.; Kinalski, M.; Terlikowski, S.J. Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer. Eur. Cytokine Netw., 2013, 24(3), 106-113.
112. Dijkgraaf, E.M.; Welters, M.J.; Nortier, J.W.; van der Burg, S.H.; Kroep, J.R. Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. Curr. Pharm. Des., 2012, 18(25), 3816-3827.
113. Lane, D.; Matte, I.; Rancourt, C.; Piché, A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer, 2011, 11, 210.
114. Guo, Y.; Nemeth, J.; O'Brien, C.; Susa, M.; Liu, X.; Zhang, Z.; Choy, E.; Mankin, H.; Hornicek, F.; Duan, Z. Effects of siltuximab on the IL-6-induced signalling pathway in ovarian cancer. Clin. Cancer Res., 2010, 16(23), 5759-5769.
115. Coward, J.I.; Kulbe, H. The role of interleukin-6 in gynaecological malignancies. Cytokine Growth Factor Rev., 2012, 23(6), 333-342.
116. Weissglas, M.G.; Schamhart, D.H.; Löwik, C.W.; Papapou-los, S.E.; Theuns, H.M.; Kurth, K-H. The role of interleukin-6 in the induction of hypercalcemia in renal cell carcinoma transplanted into nude mice. Endocrinology, 1997, 138(5), 1879-1885.
117. Rossi, J.F.; Négrier, S.; James, N.D.; Kocak, I.; Hawkins, R.; Davis, H.; Prabhakar, U.; Qin, X.; Mulders, P.; Berns, B. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br. J. Cancer, 2010, 103(8), 1154-1162.
118. Lahm, H.; Suardet, L.; Laurent, P.L.; Fischer, J.R.; Ceyhan, A.; Givel, J.C.; Odartchenko, N. Growth regulation and costimulation of human colorectal cancer cell lines by insulin-like growth factor I, II and transforming growth factor alpha. Br. J. Cancer, 1992, 65(3), 341-346.
119. Knüpfer, H.; Preiss, R. Serum interleukin-6 levels in colorectal cancer patients--a summary of published results. Int. J. Colorectal Dis., 2010, 25(2), 135-140.
120. Becker, C.; Fantini, M.C.; Wirtz, S.; Nikolaev, A.; Ki-esslich, R.; Lehr, H.A.; Galle, P.R.; Neurath, M.F. In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy. Gut, 2005, 54(7), 950-954.
121. Grivennikov, S.; Karin, E.; Terzic, J.; Mucida, D.; Yu, G-Y.; Vallabhapurapu, S.; Scheller, J.; Rose-John, S.; Cheroutre, H.; Eckmann, L.; Karin, M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell, 2009, 15(2), 103-113.
122. Wang, Z.Y.; Zhang, J.A.; Wu, X.J.; Liang, Y.F.; Lu, Y.B.; Gao, Y.C.; Dai, Y.C.; Yu, S.Y.; Jia, Y.; Fu, X.X.; Rao, X.; Xu, J.F.; Zhong, J. IL-6 inhibition reduces STAT3 activation and enhances the antitumor effect of carboplatin. Mediators Inflamm., 2016, 2016, 8026494.
123. Sebba, A. Tocilizumab: the first interleukin-6-receptor inhibitor. Am. J. Health Syst. Pharm., 2008, 65(15), 1413-1418.
124. Mima, T.; Nishimoto, N. Clinical value of blocking IL-6 receptor. Curr. Opin. Rheumatol., 2009, 21(3), 224-230.
125. Tanaka, T.; Narazaki, M.; Kishimoto, T. Therapeutic targeting of the interleukin-6 receptor. Annu. Rev. Pharmacol. Toxicol., 2012, 52, 199-219.
126. Kumanogoh, A.; Ogata, M. The study of cytokines by Japanese researchers: a historical perspective. Int. Immunol., 2010, 22(5), 341-345.
127. Galeotti, C.; Boucheron, A.; Guillaume, S.; Koné-Paut, I. Sustained remission of multicentric castleman disease in children treated with tocilizumab. Pediatr. Rheumatol., 2011, 9(1), 1.
128. Schiff, M.H.; Kremer, J.M.; Jahreis, A.; Vernon, E.; Isaacs, J.D.; van Vollenhoven, R.F. Integrated safety in tocilizumab clinical trials. Arthritis Res. Ther., 2011, 13(5), R141.
129. Isobe, A.; Sawada, K.; Kinose, Y.; Ohyagi-Hara, C.; Naka-tsuka, E.; Makino, H.; Ogura, T.; Mizuno, T.; Suzuki, N.; Morii, E.; Nakamura, K.; Sawada, I.; Toda, A.; Hashimoto, K.; Mabuchi, S.; Ohta, T.; Morishige, K.; Kurachi, H.; Kimura, T. Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer. PLoS One, 2015, 10(2), e0118080.
130. Dijkgraaf, E.M.; Santegoets, S.J.; Reyners, A.K.; Goede-mans, R.; Wouters, M.C.; Kenter, G.G.; van Erkel, A.R.; van Poelgeest, M.I.; Nijman, H.W.; van der Hoeven, J.J.; Welters, M.J.; van der Burg, S.H.; Kroep, J.R. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer. Ann. Oncol., 2015, 26(10), 2141-2149.
131. Shinriki, S.; Jono, H.; Ota, K.; Ueda, M.; Kudo, M.; Ota, T.; Oike, Y.; Endo, M.; Ibusuki, M.; Hiraki, A.; Nakayama, H.; Yoshitake, Y.; Shinohara, M.; Ando, Y. Humanized anti-interleukin-6 receptor antibody suppresses tumour angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin. Cancer Res., 2009, 15(17), 5426-5434.
132. Shinriki, S.; Jono, H.; Ueda, M.; Ota, K.; Ota, T.; Sueyoshi, T.; Oike, Y.; Ibusuki, M.; Hiraki, A.; Nakayama, H.; Shinohara, M.; Ando, Y. Interleukin-6 signalling regulates vascular endothelial growth factor-C synthesis and lymphangi-ogenesis in human oral squamous cell carcinoma. J. Pathol., 2011, 225(1), 142-150.
133. Mochizuki, D.; Adams, A.; Warner, K.A.; Zhang, Z.; Pearson, A.T.; Misawa, K.; McLean, S.A.; Wolf, G.T.; Nör, J.E. Anti-tumor effect of inhibition of IL-6 signaling in mu-coepidermoid carcinoma. Oncotarget, 2015, 6(26), 22822-22835.
134. Ando, K.; Takahashi, F.; Motojima, S.; Nakashima, K.; Kaneko, N.; Hoshi, K.; Takahashi, K. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J. Clin. Oncol., 2013, 31(6), e69-e72.
135. Fulciniti, M.; Hideshima, T.; Vermot-Desroches, C.; Pozzi, S.; Nanjappa, P.; Shen, Z.; Patel, N.; Smith, E.S.; Wang, W.; Prabhala, R.; Tai, Y.T.; Tassone, P.; Anderson, K.C.; Munshi, N.C. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin. Cancer Res., 2009, 15(23), 7144-7152.
136. Mease, P.; Strand, V.; Shalamberidze, L.; Dimic, A.; Raski-na, T.; Xu, L.-A.; Liu, Y.; Smith, J. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann. Rheum. Dis., 2012, 71(7), 1183-1139.
137. Inc., A.B. Alder Biopharmaceuticals' ALD518 antibody therapeutic reduces disease symptoms, anemia in phase 2a clinical trial in non-small cell lung cancer patients. Available from: http://www.prnewswire.com/news-releases/al-der-biopharmaceuticals-ald518-antibody-therapeutic-redu-ces-disease-symptoms-anemia-in-phase-2a-clinical-trial-in-non-small-cell-lung-cancer-patients-95718569.html
138. Bayliss, T.J.; Smith, J.T.; Schuster, M.; Dragnev, K.H.; Rigas, J.R. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin. Biol. Ther., 2011, 11(12), 1663-1668.
139. Reichert, J.M. In MAbs; Taylor & Francis, 2015, Vol. 7, pp. 1-8.
140. Adachi, Y.; Yoshio-Hoshino, N.; Aoki, C.; Nishimoto, N. VEGF targeting in mesotheliomas using an interleukin-6 signal inhibitor based on adenovirus gene delivery. Anticancer Res., 2010, 30(6), 1947-1952.
141. Hönemann, D.; Chatterjee, M.; Savino, R.; Bommert, K.; Burger, R.; Gramatzki, M.; Dörken, B.; Bargou, R.C. The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells. Int. J. Cancer, 2001, 93(5), 674-680.
142. Tassone, P.; Neri, P.; Burger, R.; Savino, R.; Shammas, M.; Catley, L.; Podar, K.; Chauhan, D.; Masciari, S.; Gozzini, A.; Tagliaferri, P.; Venuta, S.; Munshi, N.C.; Anderson, K.C. Combination therapy with interleukin-6 receptor su-perantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu in vivo model of human multiple myeloma. Clin. Cancer Res., 2005, 11(11), 4251-4258.
143. Enomoto, A.; Rho, M-C.; Fukami, A.; Hiraku, O.; Komi-yama, K.; Hayashi, M. Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist. Biochem. Biophys. Res. Commun., 2004, 323(3), 1096-1102.
144. Rose-John, S.; Waetzig, G.H.; Scheller, J.; Grötzinger, J.; Seegert, D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin. Ther. Targets, 2007, 11(5), 613-624.
145. Yasukawa, K.; Futatsugi, K.; Saito, T.; Yawata, H.; Narazaki, M.; Suzuki, H.; Taga, T.; Kishimoto, T. Association of recombinant soluble IL-6-signal transducer, gp130, with a complex of IL 6 and soluble IL-6 receptor, and establishment of an ELISA for soluble gp130. Immunol. Lett., 1992, 31(2), 123-130.
146. Melton, L.; Coombs, A. Actemra poised to launch IL-6 inhibitors. Nat. Biotechnol., 2008, 26(9), 957-959.
147. Atreya, R.; Finotto, S.; Mudter, J.; Mullberg, J.; Jostock, T.; Holtmann, M.; Kishimoto, T.; Galle, P.R.; Rose-John, S.; Neurath, M.F. Blockade of IL-6 transsignalling abrogates established experimental colitis in mice by suppression of T cell resistance against apoptosis. Gastroenterology, 2000, 118(4), A863.
148. Nowell, M.A.; Williams, A.S.; Carty, S.A.; Scheller, J.; Hayes, A.J.; Jones, G.W.; Richards, P.J.; Slinn, S.; Ernst, M.; Jenkins, B.J.; Topley, N.; Rose-John, S.; Jones, S.A. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J. Immunol., 2009, 182(1), 613-622.
149. Hatting, M.; Spannbauer, M.; Peng, J.; Al Masaoudi, M.; Sellge, G.; Nevzorova, Y.A.; Gassler, N.; Liedtke, C.; Cubero, F.J.; Trautwein, C. Lack of gp130 expression in hepatocytes attenuates tumor progression in the DEN model. Cell Death Dis., 2015, 6, e1667.
150. Hong, J.; Wang, H.; Shen, G.; Lin, D.; Lin, Y.; Ye, N.; Guo, Y.; Li, Q.; Ye, N.; Deng, C. Recombinant soluble gp130 protein reduces DEN-induced primary hepatocellular carcinoma in mice. Sci. Rep., 2016, 6, 24397.
151. Goumas, F.A.; Holmer, R.; Egberts, J.H.; Gontarewicz, A.; Heneweer, C.; Geisen, U.; Hauser, C.; Mende, M.M.; Leg-ler, K.; Rocken, C.; Becker, T.; Waetzig, G.H.; Rose-John, S.; Kalthoff, H. Rose-John, S.; Kalthoff, H. Inhibition of IL-6 signalling significantly reduces primary tumour growth and recurrencies in orthoopic xenograft models of pancreatic cancer. Int. J. Cancer, 2015, 137(5), 1035-1046.
152. Kraakman, M.J.; Kammoun, H.L.; Allen, T.L.; Deswaerte, V.; Henstridge, D.C.; Estevez, E.; Matthews, V.B.; Neill, B.; White, D.A.; Murphy, A.J.; Peijs, L.; Yang, C.; Risis, S.; Bruce, C.R.; Du, X.J.; Bobik, A.; Lee-Young, R.S.; Kingwell, B.A.; Vasanthakumar, A.; Shi, W.; Kallies, A.; Lancaster, G.I.; Rose-John, S.; Febbraio, M.A. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab., 2015, 21(3), 403-416.
153. Garbers, C.; Aparicio-Siegmund, S.; Rose-John, S. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr. Opin. Immunol., 2015, 34, 75-82.
154. Hoos, A.; Eggermont, A.M.; Janetzki, S.; Hodi, F.S.; Ibrahim, R.; Anderson, A.; Humphrey, R.; Blumenstein, B.; Old, L.; Wolchok, J. Improved endpoints for cancer immunotherapy trials. J. Natl. Cancer Inst., 2010, 102(18), 1388-1397.
155. Vatsan, R.S.; Bross, P.F.; Liu, K.; Theoret, M.; De Claro, A.R.; Lu, J.; Helms, W.; Niland, B.; Husain, S.R.; Puri, R.K. Regulation of immunotherapeutic products for cancer and FDA’s role in product development and clinical evaluation. J. Immunother. Cancer, 2013, 1(1), 5.
156. Janetzki, S.; Britten, C.M.; Kalos, M.; Levitsky, H.I.; Maecker, H.T.; Melief, C.J.; Old, L.J.; Romero, P.; Hoos, A.; Davis, M.M. “MIATA”-minimal information about T cell assays. Immunity, 2009, 31(4), 527-528.
157. Wolchok, J.D.; Hoos, A.; O’Day, S.; Weber, J.S.; Hamid, O.; Lebbé, C.; Maio, M.; Binder, M.; Bohnsack, O.; Nichol, G.; Humphrey, R.; Hodi, F.S. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin. Cancer Res., 2009, 15(23), 7412-7420.
158. Small, E.J.; Schellhammer, P.F.; Higano, C.S.; Redfern, C.H.; Nemunaitis, J.J.; Valone, F.H.; Verjee, S.S.; Jones, L.A.; Hershberg, R.M. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol., 2006, 24(19), 3089-3094.
159. Fleming, T.R.; Harrington, D.P. Counting processes and survival analysis; John Wiley & Sons, 2011.
160. Actemra Intravenous Infusion 200 Safety Information Tabulation Results From Approval to June 30; 2006.
161. Genentech, I. Available from: http://www. access-data.fda.gov/drug-satfda_docs/label/2010/125276lbl.pdf